What is Charles River Laboratories International, Inc.'s (CRL) StockRank?

MoatMap's StockRank for Charles River Laboratories International, Inc. (CRL) is 69/100, with a Buy signal. This is a composite score combining Quality (48), Value (42), and Momentum (73) factor ranks across MoatMap's 20,000+ stock universe.

Does Charles River Laboratories International, Inc. have an economic moat?

Charles River Laboratories International, Inc. (CRL) has a Quality factor score of 48/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Charles River Laboratories International, Inc. a buy, hold, or sell?

MoatMap's current signal for Charles River Laboratories International, Inc. (CRL) is Buy, based on a StockRank of 69/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Charles River Laboratories International, Inc. in?

Charles River Laboratories International, Inc. (CRL) operates in the Healthcare sector, specifically the Diagnostics & Research industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CRL

BUY

Charles River Laboratories International, Inc. · Healthcare · United States · $10.9B · Avg Vol: $196M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-5.9%

D/E

1.0x

Dividend %

—

COMPANY DESCRIPTION

Charles River Laboratories International, Inc. is a leading global contract research organization (CRO), providing a comprehensive suite of preclinical and clinical laboratory services to pharmaceutical, biotechnology, government, and academic clients. The company's competitive moat stems from its integrated service offerings, specialized scientific expertise, global operational scale, and the high switching costs for its clients in critical drug development phases. It serves as an indispensable partner in early-stage drug discovery and development.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	4.0B	4.1B	4.0B	4.0B	0.3%	4.0B	3.8B	3.9B	-1.2%
EPS	9.57	9.27	0.20	-2.91	-85.5%	-3.63	—	—	—
Shares	50.9M	51.3M	51.1M	49.2M	-3.4%	48.2M	—	—	—
Debt	3.1B	3.1B	2.7B	2.6B	-6.0%	3.1B	—	—	—
Equity	3.0B	3.6B	3.5B	3.2B	2.1%	—	—	—	—
Op CF	619.6M	683.9M	734.6M	737.6M	6.0%	607.0M	—	—	—
Inv CF	-607.9M	-563.2M	-245.1M	-209.3M	—	—	—	—	—
Fin CF	-42.4M	-85.5M	-550.9M	-536.7M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+20.5%

SMA 50SMA 200

$226.58

RSI (14)

45.2

52W High

$238.85

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

0.1%46.3

ROE

-5.9%40.0

GP/Assets

19.4%46.7

Op. Margin

15.9%77.4

FCF/Assets

7.1%78.1

Piotroski

550.0

Int. Cover

0.1x37.3

D/E Ratio

1.03x14.0

Current Ratio

1.36x21.7

Value

P/E (TTM)

—N/A

EV/EBITDA

15.2x44.3

P/FCF

21.4x57.8

P/B

3.6x37.2

P/S

2.6x59.9

Div Yield

—N/A

Momentum

52W High %

95%93.9

RS 6M

-7%66.9

SMA 50/200

1.06x76.1

EPS Rev 4W

+0.2%79.2

EPS Rev 12W

-0.1%53.9

EPS Improve

+440%95.3

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$10.9B

P/E (Forward)

17.8x

Gross Margin

34.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRL are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
CRL	Charles River Laboratories International, Inc.(you)	$10.9B	69	BUY
RVTY	Revvity, Inc.	$12.3B	65	BUY
MEDP	Medpace Holdings, Inc.	$16.8B	78	BUY
SHC	Sotera Health Company	$4.9B	66	BUY
IQV	IQVIA Holdings Inc.	$34.7B	67	BUY
WAT	Waters Corporation	$36.8B	65	BUY
A	Agilent Technologies, Inc.	$32.5B	77	BUY
VCYT	Veracyte, Inc.	$4.5B	83	STRONG BUY
GH	Guardant Health, Inc.	$19.5B	47	HOLD
ILMN	Illumina, Inc.	$29.4B	84	STRONG BUY

Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.7%

Charles River Laboratories International, Inc. (CRL) — Stock Score Summary

Charles River Laboratories International, Inc. (CRL) has a MoatMap StockRank of 69/100 based on Quality (48/100), Value (42/100), and Momentum (73/100) factor scores. The current signal is BUY.

Key Financial Metrics

Price	$226.58
Market Cap	$10.9B
P/E (Forward)	17.82
Price/Book	3.60
Return on Equity	-5.9%
Return on Invested Capital	0.1%
Debt/Equity	1.03x
Gross Margin	34.5%
Operating Margin	15.9%
Revenue Growth	1.2%
Free Cash Flow	$510M

Charles River Laboratories International, Inc. operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Charles River Laboratories International, Inc.’s (CRL) StockRank?: MoatMap’s StockRank for Charles River Laboratories International, Inc. (CRL) is 69/100, with a Buy signal. It is a composite of Quality (48), Value (42), and Momentum (73) factor ranks across MoatMap’s 20,000+ stock universe.
Does Charles River Laboratories International, Inc. have an economic moat?: Charles River Laboratories International, Inc. (CRL) has a Quality factor score of 48/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Charles River Laboratories International, Inc. a buy, hold, or sell?: MoatMap’s current signal for Charles River Laboratories International, Inc. (CRL) is Buy, based on a StockRank of 69/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Charles River Laboratories International, Inc. in?: Charles River Laboratories International, Inc. (CRL) operates in the Healthcare sector, specifically the Diagnostics & Research industry (United States).